Search

Your search keyword '"Crafoord Foundation"' showing total 2 results
Start Over Author "Crafoord Foundation" Publisher frontiers media
2 results on '"Crafoord Foundation"'

1. Hyperinflammation and Fibrosis in Severe COVID-19 Patients: Galectin-3, a Target Molecule to Consider

Author

Swedish Research Council, Lund University, Swedish Alzheimer Foundation, Swedish Brain Foundation, Royal Physiographic Society of Lund, Crafoord Foundation, Olle Engkvist Foundation, Ake Wiberg Foundation, Gun and Bertil Stohnes Foundation, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), European Commission, Ministerio de Economía y Competitividad (España), García-Revilla, Juan, Deierborg, Tomas, Venero, José L., Boza-Serrano, Antonio, Swedish Research Council, Lund University, Swedish Alzheimer Foundation, Swedish Brain Foundation, Royal Physiographic Society of Lund, Crafoord Foundation, Olle Engkvist Foundation, Ake Wiberg Foundation, Gun and Bertil Stohnes Foundation, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), European Commission, Ministerio de Economía y Competitividad (España), García-Revilla, Juan, Deierborg, Tomas, Venero, José L., and Boza-Serrano, Antonio

Abstract

COVID-19 disease have become so far the most important sanitary crisis in the XXI century. In light of the events, any clinical resource should be considered to alleviate this crisis. Severe COVID-19 cases present a so-called cytokine storm as the most life-threatening symptom accompanied by lung fibrosis. Galectin-3 has been widely described as regulator of both processes. Hereby, we present compelling evidences on the potential role of galectin-3 in COVID-19 in the regulation of the inflammatory response, fibrosis and infection progression. Moreover, we provide a strong rationale of the utility of measuring plasma galectin-3 as a prognosis biomarker for COVID-19 patients and propose that inhibition of galectin-3 represents a feasible and promising new therapeutical approach.

Published
2020

2. Hyperinflammation and Fibrosis in Severe COVID-19 Patients: Galectin-3, a Target Molecule to Consider

Author

Garcia-Revilla, Juan, Deierborg, Tomas, Venero, Jose Luis, Boza-Serrano, Antonio, [Garcia-Revilla,J, Venero,JL, Boza-Serrano,A] Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia and Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain. [Deierborg,T] Department of Experimental Medical Science, Experimental Neuroinflammation Laboratory, BMC, Lund University, Lund, Sweden. [Boza-Serrano,A] Department of Experimental Medical Sciences, Experimental Dementia Research Laboratory, BMC, Lund University, Lund, Sweden., This work was supported by grants from the Swedish Research Council (2019-06333, AB-S), and the Strong Research Environment MultiPark (Multidisciplinary Research in Parkinson’s and Alzheimer’s Disease at Lund University), Bagadilico (Linné consortium sponsored by the Swedish Research Council), the Swedish Alzheimer’s Foundation, Swedish Brain Foundation, A.E. Berger Foundation, Gyllenstiern-ska Krapperup Foundation, the Royal Physiographic Society, Crafoord Foundation, Olle Engkvist Byggmästare Foundation, Wiberg Foundation, G&J Kock Foundation, Stohnes Foundation, and Swedish Dementia Association and the Medical Faculty at Lund University. This perspective was also funded by the Spanish Ministerio de Ciencia, Innovación y Universidades/FEDER/UE RTI2018-098645-B-100, FEDER I+D+i-USE US-1265062, and US-1264806. JG-R has been funded by a grant from the Spanish Ministerio de Economia y Competitividad SAF2015-64171-R (MINECO/FEDER, EU)., Universidad de Sevilla. Departamento de Bioquímica y Biología Molecular, Swedish Research Council, Lund University, Swedish Alzheimer Foundation, Swedish Brain Foundation, Royal Physiographic Society of Lund, Crafoord Foundation, Olle Engkvist Foundation, Ake Wiberg Foundation, Gun and Bertil Stohnes Foundation, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), European Commission, and Ministerio de Economía y Competitividad (España)

Subjects
Galectina 3, Galectin 3, Galectins, Pulmonary Fibrosis, Infecciones por coronavirus, Immunology, Pneumonia, Viral, Peptidyl-Dipeptidase A, Cytokine storm, Severity of Illness Index, Betacoronavirus, Animals, Humans, Galectin-3, Molecular Targeted Therapy, Diseases::Respiratory Tract Diseases::Lung Diseases::Pulmonary Fibrosis [Medical Subject Headings], Pandemics, Inflammation, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Cytokines [Medical Subject Headings], Inflamación, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Lectins::Galectins::Galectin 3 [Medical Subject Headings], SARS-CoV-2, COVID-19, Citocinas, Blood Proteins, Biomarker, Prognosis, Fibrosis, Diseases::Respiratory Tract Diseases::Lung Diseases::Pneumonia [Medical Subject Headings], Diseases::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [Medical Subject Headings], Perspective, Host-Pathogen Interactions, Spike Glycoprotein, Coronavirus, Disease Progression, biomarker, Cytokines, Angiotensin-Converting Enzyme 2, Biomarcadores ambientales, Coronavirus Infections, Chemicals and Drugs::Biological Factors::Biological Markers::Biomarkers, Pharmacological [Medical Subject Headings], Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Inflammation [Medical Subject Headings], Biomarkers
Abstract

COVID-19 disease have become so far the most important sanitary crisis in the XXI century. In light of the events, any clinical resource should be considered to alleviate this crisis. Severe COVID-19 cases present a so-called cytokine storm as the most life-threatening symptom accompanied by lung fibrosis. Galectin-3 has been widely described as regulator of both processes. Hereby, we present compelling evidences on the potential role of galectin-3 in COVID-19 in the regulation of the inflammatory response, fibrosis and infection progression. Moreover, we provide a strong rationale of the utility of measuring plasma galectin-3 as a prognosis biomarker for COVID-19 patients and propose that inhibition of galectin-3 represents a feasible and promising new therapeutical approach., This work was supported by grants from the Swedish Research Council (2019-06333, AB-S), and the Strong Research Environment MultiPark (Multidisciplinary Research in Parkinson’s and Alzheimer’s Disease at Lund University), Bagadilico (Linné consortium sponsored by the Swedish Research Council), the Swedish Alzheimer’s Foundation, Swedish Brain Foundation, A.E. Berger Foundation, Gyllenstiern-ska Krapperup Foundation, the Royal Physiographic Society, Crafoord Foundation, Olle Engkvist Byggmästare Foundation, Wiberg Foundation, G&J Kock Foundation, Stohnes Foundation, and Swedish Dementia Association and the Medical Faculty at Lund University. This perspective was also funded by the Spanish Ministerio de Ciencia, Innovación y Universidades/FEDER/UE RTI2018-098645-B-100, FEDER ICDCi-USE US-1265062, and US-1264806. JG-R has been funded by a grant from the Spanish Ministerio de Economia y Competitividad SAF2015-64171-R (MINECO/FEDER, EU).

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results